{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-024512","form_type":"8-K","ticker":null,"cik":"0001843762","company_name":"EQRx, Inc.","filed_at":"2023-02-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:47.077681+00:00","generated_at":"2026-06-19T03:20:36.131342+00:00","sec_items":["2.02","2.05","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"EQRx Q4 net loss $22.2M, full year $169.1M; cuts headcount 18% to ~300 employees","bullets":["Net loss Q4 2022 $22.2M vs net income $1.2M in Q4 2021; full year net loss $169.1M vs $100.0M in 2021.","Cash, cash equivalents and short-term investments $1.4B at Dec 31, 2022; runway into 2028.","2023 cash used in operations expected <$275M.","Restructuring: 18% headcount reduction to ~300 employees by end of Q1 2023; expected annualized cash savings ~$18M; one-time costs ~$4M.","Pipeline: MAAs for aumolertinib and sugemalimab accepted by MHRA and EMA; Phase 3 trial for lerociclib in endometrial cancer expected 1H 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-024512","json":"https://secwatch.observer/filing/0001104659-23-024512.json","markdown":"https://secwatch.observer/filing/0001104659-23-024512.md","text":"https://secwatch.observer/filing/0001104659-23-024512.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1843762/000110465923024512/0001104659-23-024512-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1843762/000110465923024512/tm237658d2_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T03:20:36.131342+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"54e3ceb4751c5c98f6b2ba976b2ae3c9d1518ecb","claim":"EQRx, Inc. reported the fourth quarter ended December 31, 2022 results: net income $22.2 million.","evidence_excerpt":"Net loss totaled $22.2 million for the fourth quarter of 2022, as compared to net income of $1.2 million for the same period in 2021","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1843762/000110465923024512/0001104659-23-024512-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter ended December 31, 2022"},{"label":"Net income","value":"$22.2 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"2728e7e2ad22ff98a6241a293f83c9aea67017dc","claim":"EQRx, Inc. announced a restructuring with charges of approximately $4.0 million (an 18% decrease in headcount by the end of the first quarter of 2023 to approximately 300 employees).","evidence_excerpt":"On February 19, 2023, the board of directors of EQRx approved a restructuring plan (the Plan) to further increase EQRx’s operational efficiencies and streamline expenses, including an 18% decrease in headcount by the end of the first quarter of 2023 to approximately 300 employees, resulting from a reduction in force as well as not filling positions following departures. These efforts are expected to result in approximately $18.0 million in annualized cash savings. One-time payments associated with the reduction in force are expected to be approximately $4.0 million.","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1843762/000110465923024512/0001104659-23-024512-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Charge","value":"approximately $4.0 million"},{"label":"Headcount","value":"an 18% decrease in headcount by the end of the first quarter of 2023 to approximately 300 employees"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}